Antimicrobial-resistant infections

Conference Coverage

Ribaxamase reduced new CDI infection by 71%

Hospitalized patients who received the investigational oral agent ribaxamase had a 71% reduction in the development of new Clostridium difficile...

Conference Coverage

IDWeek 2017 opens in San Diego

The IDWeek 2017 symposia, oral abstract sessions, and poster abstract sessions are the highlights.

Pages